KR102491439B1 - 아비라테론 아세테이트 제제 및 사용 방법 - Google Patents

아비라테론 아세테이트 제제 및 사용 방법 Download PDF

Info

Publication number
KR102491439B1
KR102491439B1 KR1020177008938A KR20177008938A KR102491439B1 KR 102491439 B1 KR102491439 B1 KR 102491439B1 KR 1020177008938 A KR1020177008938 A KR 1020177008938A KR 20177008938 A KR20177008938 A KR 20177008938A KR 102491439 B1 KR102491439 B1 KR 102491439B1
Authority
KR
South Korea
Prior art keywords
abiraterone acetate
dosage form
unit dosage
dose
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177008938A
Other languages
English (en)
Korean (ko)
Other versions
KR20170070025A (ko
Inventor
마우라 머피
폴 네메스
에이치. 윌리엄 보쉬
매튜 칼라한
사티야 바미디파티
제이슨 콜먼
크리스토퍼 힐
마르크 노렛
Original Assignee
썬 파마슈티칼 인더스트리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102491439(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by 썬 파마슈티칼 인더스트리스 리미티드 filed Critical 썬 파마슈티칼 인더스트리스 리미티드
Priority to KR1020237001893A priority Critical patent/KR102617537B1/ko
Publication of KR20170070025A publication Critical patent/KR20170070025A/ko
Application granted granted Critical
Publication of KR102491439B1 publication Critical patent/KR102491439B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
KR1020177008938A 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법 Active KR102491439B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237001893A KR102617537B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 2015-05-08
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001893A Division KR102617537B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20170070025A KR20170070025A (ko) 2017-06-21
KR102491439B1 true KR102491439B1 (ko) 2023-01-25

Family

ID=55533897

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177008938A Active KR102491439B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법
KR1020237001893A Active KR102617537B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237001893A Active KR102617537B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법

Country Status (17)

Country Link
EP (1) EP3193857A4 (cg-RX-API-DMAC10.html)
JP (1) JP2017528457A (cg-RX-API-DMAC10.html)
KR (2) KR102491439B1 (cg-RX-API-DMAC10.html)
CN (1) CN106687112A (cg-RX-API-DMAC10.html)
AP (1) AP2017009804A0 (cg-RX-API-DMAC10.html)
AU (1) AU2015317466A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017003219A2 (cg-RX-API-DMAC10.html)
CA (1) CA2958316A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017002472A2 (cg-RX-API-DMAC10.html)
EA (1) EA201790650A1 (cg-RX-API-DMAC10.html)
IL (1) IL250270B (cg-RX-API-DMAC10.html)
MD (1) MD20170048A2 (cg-RX-API-DMAC10.html)
MX (1) MX2017003525A (cg-RX-API-DMAC10.html)
PH (1) PH12017500239A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201701139YA (cg-RX-API-DMAC10.html)
TN (2) TN2018000318A1 (cg-RX-API-DMAC10.html)
WO (1) WO2016044701A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
JP2022523704A (ja) * 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ．ベー． アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014145813A1 (en) 2013-03-15 2014-09-18 Iceutica Inc. Abiraterone acetate formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014145813A1 (en) 2013-03-15 2014-09-18 Iceutica Inc. Abiraterone acetate formulation
KR102121404B1 (ko) 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제

Also Published As

Publication number Publication date
SG11201701139YA (en) 2017-03-30
CO2017002472A2 (es) 2017-07-11
KR20230014878A (ko) 2023-01-30
TN2018000318A1 (en) 2020-01-16
JP2017528457A (ja) 2017-09-28
MD20170048A2 (ro) 2017-08-31
TN2017000098A1 (en) 2018-10-19
AU2015317466A1 (en) 2017-02-23
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
PH12017500239A1 (en) 2017-07-03
EP3193857A1 (en) 2017-07-26
WO2016044701A1 (en) 2016-03-24
BR112017003219A2 (pt) 2017-11-28
EP3193857A4 (en) 2018-04-11
CN106687112A (zh) 2017-05-17
MX2017003525A (es) 2017-06-21
KR102617537B1 (ko) 2023-12-22
IL250270A0 (en) 2017-03-30
KR20170070025A (ko) 2017-06-21
CA2958316A1 (en) 2016-03-24
EA201790650A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
JP7752150B2 (ja) アビラテロン酢酸エステル製剤
KR102617537B1 (ko) 아비라테론 아세테이트 제제 및 사용 방법
US9889144B2 (en) Abiraterone acetate formulation and methods of use
EP2421510B1 (en) Production of encapsulated nanoparticles at commercial scale
US10292990B2 (en) Abiraterone steroid formulation
HK40018807A (en) Abiraterone acetate formulation
HK40018807B (en) Abiraterone acetate formulation
HK40020084B (en) Abiraterone acetate formulation
OA18485A (en) Abiraterone acetate formulation and methods of use.
HK1234990A1 (en) Abiraterone acetate formulation and methods of use
HK1220162B (en) Abiraterone acetate formulation
OA18169A (en) Abiraterone acetate formulation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4